Funding for this research was provided by:
Received: 14 January 2022
Accepted: 26 April 2022
First Online: 12 May 2022
: Informed verbal consent for the off-label use of empagliflozin was obtained from the parents of our patients prior to treatment commencement. This is a retrospective collection of anonymized data collected during routine patient care which, in line with the declaration of Helsinki, neither individual patients consents nor formal research ethics committee approval was required.
: All patients provided written consent for publication.
: The authors declare they have no competing interests.